psp-tauopathy

PSP Tauopathy Mechanisms

Overview

Progressive Supranuclear Palsy (PSP) is the prototypical 4-repeat (4R) tauopathy, a class of neurodegenerative disorders characterized by the predominant accumulation of 4R tau protein isoforms. PSP is also known as Steele-Richardson-Olszewski syndrome, named after the three neurologists who first described it in 1964[@williams2020]. Unlike Alzheimer's disease (AD), which features equal representation of 3R and 4R tau in neurofibrillary tangles, PSP selectively accumulates 4R tau isoforms, reflecting a distinct molecular pathophysiology[@goedert2018].

This page synthesizes the core mechanistic knowledge of PSP tauopathy, covering tau isoform biology, clinical subtypes, genetic architecture, glial pathology, tau PET imaging, and the therapeutic pipeline. PSP serves as the archetype for understanding how isoform-specific tau dysregulation drives selective neuronal vulnerability and disease progression.

Tau Isoform Biology: 4R Specificity

MAPT Gene and Alternative Splicing

The [MAPT gene](/genes/mapt) on chromosome 17q21 encodes tau protein, which exists in six isoforms in the adult human brain. These isoforms arise from alternative mRNA splicing of exons 2, 3, and 10. The critical distinction is the inclusion or exclusion of exon 10:

• 3R tau isoforms: Exclude exon 10, resulting in three microtubule-binding repeat domains (R1, R2, R3)
• 4R tau isoforms: Include exon 10, adding a fourth repeat domain (R1, R2, R3, R4)

PSP Tauopathy Mechanisms

Overview

Progressive Supranuclear Palsy (PSP) is the prototypical 4-repeat (4R) tauopathy, a class of neurodegenerative disorders characterized by the predominant accumulation of 4R tau protein isoforms. PSP is also known as Steele-Richardson-Olszewski syndrome, named after the three neurologists who first described it in 1964[@williams2020]. Unlike Alzheimer's disease (AD), which features equal representation of 3R and 4R tau in neurofibrillary tangles, PSP selectively accumulates 4R tau isoforms, reflecting a distinct molecular pathophysiology[@goedert2018].

This page synthesizes the core mechanistic knowledge of PSP tauopathy, covering tau isoform biology, clinical subtypes, genetic architecture, glial pathology, tau PET imaging, and the therapeutic pipeline. PSP serves as the archetype for understanding how isoform-specific tau dysregulation drives selective neuronal vulnerability and disease progression.

Tau Isoform Biology: 4R Specificity

MAPT Gene and Alternative Splicing

The [MAPT gene](/genes/mapt) on chromosome 17q21 encodes tau protein, which exists in six isoforms in the adult human brain. These isoforms arise from alternative mRNA splicing of exons 2, 3, and 10. The critical distinction is the inclusion or exclusion of exon 10:

• 3R tau isoforms: Exclude exon 10, resulting in three microtubule-binding repeat domains (R1, R2, R3)
• 4R tau isoforms: Include exon 10, adding a fourth repeat domain (R1, R2, R3, R4)

Why 4R Tau Accumulates in PSP

PSP demonstrates marked predominance of 4R tau in all inclusions — neuronal tangles, glial inclusions, and neuropil threads. Multiple mechanisms drive this imbalance:

1. Exon 10 Splicing Dysregulation
Changes in splicing factor activity shift the 3R:4R balance toward 4R. SF3B1, SRSF2, andhnRNPA1 are implicated in this shift. Both neuronal and glial cells in PSP show altered splicing patterns that favor exon 10 inclusion[@bhatt2024].

2. Enhanced 4R Aggregation Propensity
4R tau has higher aggregation propensity than 3R tau due to:

• The additional R4 repeat contains the PHF6* motif (VQIVYK), a primary nucleation site absent in 3R tau
• The extra cysteine residue at position 322 forms disulfide-stabilized oligomers
• Greater hydrophobic surface area in the microtubule-binding domain

4R vs 3R+4R: Comparison with Alzheimer's Disease

| Feature | PSP (4R Tauopathy) | AD (3R+4R Tauopathy) |
|---------|-------------------|----------------------|
| Tau isoform composition | 4R only (~100%) | Equal 3R and 4R (~50:50) |
| Primary filament type | Straight filaments (SF) | Paired helical filaments (PHF) |
| Filament core structure | C-shaped protofilament, excludes R1 | Extended β-sheets across all repeats |
| Key phospho-epitopes | pS356, pS262 | pT181, pS396, pS404 |
| Astroglial pathology | Tufted astrocytes | Neurofibrillary tangles in astrocytes (rare) |
| Oligodendroglial pathology | Coiled bodies | Oligodendroglial tau (less prominent) |
| Amyloid co-pathology | Rare (~15% of cases) | Universal (~100%) |
| Clinical onset | 60-70 years, rapid progression | 65-80 years, slower progression |
| Typical survival | 5-7 years | 8-12 years[@goedert2018][@falcon2019] |

Key Phospho-Epitopes in PSP

The phosphorylation pattern of tau in PSP differs from AD and other tauopathies:

• pS356 (Serine 356): The most PSP-specific phospho-epitope. Present in >95% of PSP cases, absent or rare in AD and CBD. Correlates with clinical severity and disease duration[@Morris2024].
• pS262: Present in both PSP and CBD, less common in AD. Associated with microtubule destabilization.
• pS396 and pS404: Present but less prominent than in AD. The overall phosphorylation burden is lower in PSP than AD.
• pT181: Elevated in PSP CSF but less than AD. A useful biomarker but not disease-specific[@chen2024].

PSP Clinical Subtypes

NINDS-SPSP Classification (1996)

The original NINDS-SPSP criteria recognized one clinical phenotype[@williams2020]. However, it became clear that PSP encompasses a spectrum of clinical presentations that correlate with underlying regional tau burden.

MDS-PSP Criteria (2017)

The Movement Disorder Society (MDS) 2017 criteria formalized multiple clinical subtypes[@stamelou2023][@boxer2017]:

Richardson Syndrome (PSP-RS)

The classic phenotype, accounting for ~50% of PSP cases:

• Vertical supranuclear gaze palsy (VNGP), especially downward gaze
• Early postural instability with falls (within first year)
• Symmetric akinesia-rigid syndrome, poorly responsive to levodopa
• Frontal cognitive impairment (executive dysfunction, apathy)
• Axial rigidity greater than limb rigidity
• Pseudobulbar affect

PSP with Parkinsonism (PSP-P)

Mimics Parkinson's disease early in the course:

• Asymmetric onset with tremor
• Initial levodopa responsiveness (diminishes over time)
• Slow progression to classic PSP features
• Later development of gaze palsy and falls

PSP with Progressive Apraxia of Speech (PSP-PAG)

Characterized by primary speech impairment:

• Non-fluent/agrammatic apraxia of speech
• Speech apraxia precedes parkinsonism
• Language variants overlap with primary progressive apraxia
• Tau burden concentrated in language networks[@stamelou2023]

PSP with Corticobasal Presentation (PSP-CBS)

Overlaps with corticobasal syndrome:

• Asymmetric rigidity and apraxia
• Alien limb phenomenon
• Cortical sensory loss
• Axial rigidity with limb dystonia

PSP with Pure Akinesia with Gait Freezing (PSP-PAGF)

Predominantly motor phenotype:

• Gait ignition failure
• Freezing of gait
• No or minimal cognitive impairment early
• Micrographia and hypophonia

PSP with Posterior Cortical Atrophy (PSP-PCA)

Visual processing variant:

• Balint syndrome features
• Simultagnosia, optic ataxia
• Dorsal stream dysfunction
• Relatively preserved memory

PSP with Primarily Cerebellar Ataxia (PSP-PI)

Rare variant with cerebellar involvement:

• Progressive ataxia
• Dysarthria
• Oculomotor abnormalities
• Later cognitive decline

Subtype Pathological Correlates

The clinical heterogeneity of PSP subtypes reflects differential regional vulnerability to tau pathology:

| Subtype | Primary Tau Burden Regions | Gait | Speech | Cognition |
|---------|--------------------------|------|--------|-----------|
| PSP-RS | Brainstem, basal ganglia | Early falls | Dysarthria | Executive |
| PSP-P | Basal ganglia, cortical | Variable | Variable | Executive |
| PSP-PAG | Motor cortex, basal ganglia | Preserved | Apraxia | Language |
| PSP-CBS | Frontoparietal cortex | Late falls | Dysarthria | Visuospatial |
| PSP-PAGF | Frontal-striatal | Freezing | Variable | Relatively spared |
| PSP-PCA | Occipitoparietal cortex | Variable | Variable | Visuospatial |
| PSP-PI | Brainstem, cerebellum | Ataxic gait | Dysarthria | Executive[@stamelou2023] |

MAPT Genetics and H1/H2 Haplotypes

MAPT H1/H2 Haplotype Structure

The MAPT gene exists in two major haplogroups defined by a ~1.1 Mb inversion polymorphism on chromosome 17q21:

• H1 haplotype: The ancestral, high-risk haplotype for tauopathies. Associated with increased MAPT expression, greater 4R tau production, and higher risk of PSP and CBD.
• H2 haplotype: The derived, protective haplotype, found primarily in Europeans. Inverts the H1 region, associated with reduced tau expression and protective against PSP[@wen2021].

H1/H2 and PSP Risk

Genome-wide association studies have demonstrated that the H1 haplotype is the major genetic risk factor for PSP:

| MAPT Genotype | PSP Risk | Mechanism |
|--------------|----------|-----------|
| H1/H1 | ~3-fold increased risk | Increased 4R tau expression, higher exon 10 splicing |
| H1/H2 | Intermediate risk | Partial protection from H2 haplotype |
| H2/H2 | Lowest risk | Reduced MAPT expression, lower 4R:3R ratio |

The H1 haplotype is in nearly complete linkage disequilibrium with the PSP risk allele identified in GWAS studies[@hoglinger2011][@wen2021].

GWAS-Identified PSP Risk Genes

Beyond MAPT, several other genetic loci influence PSP susceptibility[@hoglinger2011][@jabbari2018]:

| Gene | Function | Mechanism |
|------|----------|-----------|
| STX6 (Syntaxin 6) | Vesicle trafficking | Alters endosomal sorting, affects tau clearance |
| EML5 | Microtubule stability | Modifies neuronal cytoskeletal dynamics |
| MOBP (Myelin-Associated Oligodendrocyte Protein) | Myelin integrity | Affects oligodendrocyte vulnerability |
| SLCO1A2 | Organic anion transport | May affect drug delivery to CNS |
| TNIP1 | NF-κB regulation | Modulates neuroinflammation |
| PM20D1 | NPF2/DFNB25 | Lysosomal function, potential role in tau clearance |

MAPT Mutations Causing PSP-Like Phenotypes

While most PSP cases are sporadic, specific MAPT mutations can cause PSP-like phenotypes:

| Mutation | Effect on Tau | Phenotype |
|----------|--------------|-----------|
| N279K | Increases exon 10 splicing | PSP-like, earlier onset |
| P301L | Increases exon 10 splicing | PSP/FTD spectrum |
| S305S | Increases exon 10 splicing | PSP phenotype |
| +10 intronic | Activates cryptic splice site | PSP with parkinsonism |
| R406W | Reduces microtubule binding | PSP-like, memory prominent |

Tau PET Imaging in PSP

Flortaucipir (18F-AV-1451, T807)

Flortaucipir is the most extensively studied tau PET ligand, originally developed for AD[@lowe2024].

Binding Characteristics in PSP:

• Binds with lower affinity to PSP tau straight filaments compared to AD paired helical filaments
• Characteristic binding in globus pallidus and subthalamic nucleus
• Brainstem binding is more limited than expected given pathology
• Shows good correlation with clinical severity and disease duration[@malpetti2024][@chen2024]

| Region | PSP (Flortaucipir) | CBD (Flortaucipir) | AD (Flortaucipir) |
|--------|-------------------|--------------------|--------------------|
| Globus pallidus | ++ (prominent) | ++ | + (variable) |
| Subthalamic nucleus | ++ | + | + (variable) |
| Brainstem | + (moderate) | + | +++ (caudate) |
| Motor cortex | + (variable) | ++ (asymmetric) | + |
| Frontal cortex | + (variable) | ++ | +++ |
| Posterior cortex | + (rare) | + | +++ (temporal) |

Clinical Utility:

• Helps differentiate PSP from PD and MSA
• Less useful for PSP vs CBD differentiation
• Subcortical binding pattern characteristic of PSP[@koga2024]

PM-PBB3 (11C-PM-PBB3)

A second-generation tau PET ligand with higher affinity for straight filaments characteristic of 4R tauopathies[@andreone2024]:

• Higher binding affinity for PSP tau compared to flortaucipir
• Better visualization of brainstem tau burden
• Shows promise for distinguishing 4R tauopathies from AD
• Still primarily in research settings

4R-Selective Tracers

Next-generation tracers specifically targeting 4R tau structures are under development[@andreone2024]:

• Binds preferentially to 4R tau conformations over 3R+4R
• Higher signal-to-background in PSP vs current tracers
• Potential for earlier diagnosis and treatment monitoring

Biomarker Correlations

| Tau PET Finding | Clinical Correlation | Utility |
|----------------|---------------------|---------|
| Pallidal burden | Disease severity, falls | Prognostic marker |
| Subthalamic signal | PSP-RS diagnosis | Diagnostic support |
| Cortical binding | CBD vs PSP distinction | Differential diagnosis |
| Longitudinal change | Disease progression | Trial endpoint[@chen2024] |

Glial Tau Pathology

Tufted Astrocytes — The Hallmark of PSP

Tufted astrocytes are pathognomonic for PSP, distinguishing it from other 4R tauopathies[@komori2014][@smith2025]:

Morphological Features:

• Tau-positive inclusions in astrocytic processes radiating from the cell body
• Forms a "tufted" pattern, hence the name
• Located primarily in the striatum, precentral gyrus, and brainstem
• Detectable with AT8 (pS202/pT205) and pS396 antibodies

• Striatum (caudate, putamen): Most prominent
• Precentral gyrus (motor cortex): Characteristic
• Brainstem nuclei: Variable
• Hippocampus: Rare, unlike AD

• Precede neuronal loss in many regions
• Correlate with clinical phenotype severity
• May contribute to astrocyte dysfunction and neuroinflammation
• Different from astrocytic plaques in CBD[@honda2024]

Coiled Bodies (Oligodendroglial Inclusions)

Coiled bodies are tau-positive inclusions in oligodendrocytes, characteristic of PSP[@komori2014]:

Morphological Features:

• Flame-shaped or crescent-shaped inclusions
• Located in the oligodendrocyte perinuclear region
• Composed of 4R tau, hyperphosphorylated
• Detectable with Gallyas silver stain and AT8

• Predominant in: white matter tracts (corona radiata, internal capsule)
• Brainstem: pontine base, cerebellar peduncles
• Striatum: variable

• Oligodendrocyte dysfunction may precede neuronal loss
• Contributes to white matter degeneration
• May impair axonal transport
• Correlates with clinical progression rate[@honda2024]

Astrocytic vs CBD Astroglial Pathology

| Feature | PSP (Tufted Astrocytes) | CBD (Astrocytic Plaques) |
|---------|------------------------|--------------------------|
| Morphology | Thorn-shaped, radiating processes | Annular plaque pattern |
| Location | Striatum, motor cortex, brainstem | Cortex, subcortical |
| Distribution | Perivascular, periventricular | Diffuse cortical |
| Immunostaining | AT8+, pS396+ | AT8+, pS396+ |
| Specificity | Pathognomonic for PSP | Characteristic of CBD |
| Correlation | Disease severity | Cortical dysfunction |

Microglial Responses in PSP

Microglial activation accompanies tau pathology in PSP[@honda2024]:

• NLRP3 inflammasome activation in response to tau aggregates
• Pro-inflammatory cytokine release: IL-1β, TNF-α, IL-6
• TREM2 involvement: TREM2 variants modify microglial response to tau
• Interaction with tau propagation: Microglia may facilitate extracellular tau spread
• Therapeutic target: Anti-inflammatory approaches may modulate tau toxicity

Therapeutic Pipeline for PSP

Disease-Modifying Approaches

Anti-Tau Antibodies

| Agent | Target | Mechanism | Phase | Key Results |
|-------|--------|-----------|-------|-------------|
| BIIB080 (Cinmeremab) | Pan-tau (N-terminal) | Binds extracellular tau, promotes clearance | Phase 1/2 (PSP) | Reduced CSF tau, acceptable safety[@muller2025] |
| 萨罗珠单抗 (Sartumab, ABBV-8E12) | Aggregated tau | Targets misfolded tau conformations | Phase 2 (PSP) | Safety established, efficacy pending[@sato2024] |
| Gosuranemab (BIIB092) | N-terminal tau | Blocks extracellular tau propagation | Phase 2 (PSP) | Did not meet primary endpoint, target engagement shown[@siegler2023] |
| Semorinemab (RO7105705) | Tau oligomers | Targets toxic oligomeric species | Phase 2 (PSP) | Ongoing[@mendonca2024] |
| UCB 0107 | Phospho-tau | Targets specific phospho-epitopes | Phase 1/2 | Recruiting[@siegler2023] |

BIIB080 (Cinmeremab): An antisense approach via antibody — phase 1 results demonstrated dose-dependent reduction in CSF total tau and p-tau181 in PSP patients. The antibody targets the N-terminal region common to all tau isoforms, potentially enhancing clearance of both 3R and 4R species[@muller2025].

萨罗珠单抗 (Sartumab): Phase 2 trials showed acceptable safety and tolerability in PSP patients. Mechanistic studies suggest binding to aggregated tau species with subsequent Fc-mediated microglial clearance[@sato2024].

MAPT-Targeting ASOs

Antisense oligonucleotides directly targeting MAPT mRNA represent a promising approach[@muller2025]:

• BIIB080: MAPT-targeting ASO administered intrathecally. Phase 1 demonstrated dose-dependent reduction in CSF tau proteins in PSP and AD patients. Reduction of 4R tau species is particularly relevant for PSP.
• Mode of action: ASOs promote RNase H-mediated degradation of MAPT mRNA, reducing both 3R and 4R tau production
• Clinical benefit: Beyond biomarker reduction, trials assess clinical endpoints (PSP-RS, PSPRS scores)

Tau Aggregation Inhibitors

| Agent | Mechanism | Phase | Status |
|-------|-----------|-------|--------|
| LMTM (Hydromethylthionine) | Tau aggregation inhibition, mitochondrial function | Phase 3 | Mixed results, post-hoc benefit in mild PSP[@siegler2023] |
| TPI-287 | Microtubule stabilizer, 4R-specific | Phase 1 | Discontinued due to toxicity |
| Davunetide (AL-108) | Microtubule stabilizer, neuroprotective peptide | Phase 2/3 | Failed primary endpoint[@boxer2017] |

Neuroprotective Approaches

| Target | Approach | Stage | Rationale |
|--------|----------|-------|-----------|
| GSK-3β | Kinase inhibitors | Preclinical | Reduce tau phosphorylation |
| mTOR | Rapalogs (sirolimus, everolimus) | Preclinical | Enhance autophagy |
| TREM2 | Agonist antibodies | Preclinical | Modulate microglial response |
| Iron chelation | Deferiprone | Phase 2 | Reduce brain iron accumulation |

Symptomatic Treatments

Motor Symptoms

| Treatment | Mechanism | Response in PSP |
|-----------|-----------|-----------------|
| Levodopa/Carbidopa | Dopamine replacement | Minimal (~20% transient benefit) |
| Amantadine | NMDA antagonist | May reduce falls, anecdotal |
| Zolpidem | GABA-A modulator | Some improvement in axial symptoms |
| Botulinum toxin | Neuromuscular blockade | For cervical dystonia |

Non-Motor Symptoms

| Symptom | Treatment Options |
|---------|-----------------|
| Dysphagia | Swallowing therapy, dietary modification, PEG tube |
| Depression/apathy | SSRIs, SNRIs, behavioral approaches |
| Cognitive impairment | Cholinesterase inhibitors (limited benefit) |
| Sleep disturbances | Melatonin, clonazepam for REM behavior disorder |
| Urinary dysfunction | Anticholinergics (oxybutynin), catheterization[@mendonca2024] |

Clinical Trial Considerations for PSP

Patient stratification:

• PSP subtype matters — PSP-RS most represented in trials
• Genetic testing (MAPT H1/H2) may inform enrollment
• Biomarker confirmation (tau PET, CSF p-tau181/217) improves diagnosis

• PSP Rating Scale (PSPRS): Primary endpoint in most trials
• MDS-UPDRS Part III: Motor subsection
• MoCA: Cognitive screening
• Timed Up and Go: Gait assessment
• Vertical saccade velocity: Oculomotor function[@boxer2017]

Comparison of PSP, CBD, and AD: Tauopathy Matrix

Clinical Comparison

| Feature | PSP | CBD | AD |
|---------|-----|-----|-----|
| Core clinical syndrome | Vertical gaze palsy + postural instability | Asymmetric apraxia + parkinsonism | Memory impairment |
| Ocular motor findings | Supranuclear gaze palsy (vertical > horizontal) | Variable, usually absent early | Rare |
| Parkinsonism | Symmetric, axial > limb | Asymmetric, limb > axial | Minimal |
| Cortical signs | Frontal (disinhibition) | Alien limb, apraxia, cortical sensory loss | Memory, visuospatial |
| Response to levodopa | Poor | Poor to moderate | Not applicable |
| Gait/falls | Early, characteristic | Variable | Variable, late |
| Cognitive profile | Executive dysfunction | Visuospatial, language | Memory encoding[@dickson2018] |

Pathological Comparison

| Feature | PSP | CBD | AD |
|---------|-----|-----|-----|
| Tau isoform | 4R predominant | 4R predominant | 3R + 4R |
| Primary filament type | Straight filaments | Straight + twisted ribbons | Paired helical filaments |
| Filament core | C-shaped, excludes R1 | C-shaped, variant packing | Extended β-sheets |
| Neuronal inclusions | Globose tangles | Ballooned neurons, tangles | Neurofibrillary tangles |
| Astroglial inclusions | Tufted astrocytes | Astrocytic plaques | Rare, if any |
| Oligodendroglial inclusions | Coiled bodies | Fewer coiled bodies | Oligodendroglial tau |
| Regional distribution | Brainstem > basal ganglia > cortex | Cortex > basal ganglia > brainstem | Cortex (entorhinal > limbic > isocortical) |
| Amyloid co-pathology | ~15% (low) | ~20% (low) | ~100% (defining) |
| Lewy body co-pathology | ~10% | ~5% | ~20%[@kovacs2020][@falcon2019] |

Molecular Comparison

| Molecular Feature | PSP | CBD | AD |
|-------------------|-----|-----|-----|
| Key phospho-epitopes | pS356, pS262 | pS262, pS396 | pT181, pS396, pS404 |
| Key acetylation sites | K274, K281 | K280, K281 | K280, K369 |
| MAPT haplotype risk | H1/H1 (strong) | H1/H1 (moderate) | H1/H1 (weak) |
| MAPT mutations | Rare | Rare | Rare |
| Tau seeding potency | Moderate | Moderate-high | High |
| Tau strain characteristics | PSP-specific (straight filament) | CBD-specific (twisted ribbons) | AD-specific (PHF)[@koga2023] |

Therapeutic Considerations

| Therapeutic Approach | PSP | CBD | AD |
|---------------------|-----|-----|-----|
| Anti-tau antibodies (pan-tau) | Applicable | Applicable | Applicable |
| Anti-tau antibodies (4R-specific) | More relevant | More relevant | Less relevant |
| Aggregation inhibitors | Relevant | Relevant | Relevant |
| ASOs targeting MAPT | High relevance (reduces 4R) | High relevance (reduces 4R) | Moderate (reduces all tau) |
| Amyloid-targeting therapies | Not applicable | Not applicable | Applicable |
| Anti-inflammatory (TREM2) | Applicable | Applicable | Applicable[@mendonca2024] |

Tau Propagation in PSP

Prion-Like Spreading Mechanism

Tau pathology in PSP spreads through neural networks in a prion-like manner[@chen2025][@brendza2023]:

1. Tau Release

• Pathological tau is released at synapses
• Extracellular tau species include monomers, oligomers, and fibrils
• Release is activity-dependent and may be enhanced by neuronal firing

• Neurons and glia take up extracellular tau via various mechanisms:
• Macropinocytosis (primary route for fibrillar tau)
• Receptor-mediated endocytosis (LRP1, HSPGs)
• Tunneling nanotubes (direct cell-to-cell transfer)
• Exosome-associated tau (distinct species)

• Exogenous tau seeds convert native tau to pathological conformation
• The seed conformation determines the product conformation (strain fidelity)
• PSP tau seeds produce PSP-type filaments (strain-specific)

• Connected neurons take up tau from synaptic terminals of affected neurons
• The pattern of spread follows anatomical connectivity
• In PSP, this leads to brainstem-to-cortex progression[@brendza2023]

Network Propagation Pattern in PSP

Early (Brainstem)

• Substantia nigra pars compacta: Tau accumulation begins in dopaminergic neurons
• Globus pallidus: Direct synaptic targets with severe involvement
• Subthalamic nucleus: High-frequency firing neurons particularly vulnerable

• Thalamus: Relay nuclei become involved
• Pontine base: Facilitates brainstem-cortical spread

• Motor cortex: Upper motor neuron involvement
• Prefrontal cortex: Executive dysfunction
• Posterior cortex: Variable["@chen2025"]

Tau Strain Diversity in PSP

Different PSP phenotypes may reflect distinct tau strain properties[@koga2023]:

• PSP-RS tau may have different conformational properties than PSP-P
• Regional differences in tau structure (brainstem vs cortical)
• Strain stability through serial passaging
• Potential for strain-specific diagnostics and therapeutics

Cell-Type Specific Vulnerability

Neuronal Vulnerability:

• Dopaminergic neurons of substantia nigra: High vulnerability due to neuromelanin binding and oxidative stress
• Purkinje cells of cerebellum: Variable involvement
• Pyramidal neurons: Layer V motor cortex particularly affected

• Astrocytes: Tufted morphology in PSP
• Oligodendrocytes: Coiled body formation
• Microglia: Reactive, may facilitate propagation

Tau Oligomer Biology in PSP

Oligomeric Species in PSP

Oligomeric tau represents the most toxic species in tauopathies, including PSP[@patel2025]:

1. Early Oligomers (dimers, trimers)

• Form from hyperphosphorylated tau monomers
• Metastable, transient species
• Highly neurotoxic, disrupt synaptic function

• Stable oligomeric assemblies
• Membrane-permeabilizing activity
• Present in PSP brain tissue and CSF

• Prefibrillar aggregates
• Seeds for mature filament formation
• May spread between cells

PSP-Specific Oligomer Properties

| Property | PSP Oligomers | AD Oligomers | CBD Oligomers |
|----------|---------------|---------------|----------------|
| Size | 6-10mers (compact) | 12-20mers (larger) | 8-14mers |
| Morphology | Short, round | Elongated, fibrillar | Variable |
| pS356 content | High (specific) | Low | Low-moderate |
| Membrane binding | High | Moderate | Moderate |
| Synaptic localization | Prominent | Variable | Moderate |
| Neurotoxicity potency | High | Very high | High[@patel2025] |

Mechanisms of Oligomer Toxicity

Synaptic Dysfunction:

• Bind to NMDA and AMPA receptors
• Impair long-term potentiation (LTP)
• Disrupt synaptic vesicle trafficking
• Lead to spine loss and cognitive decline

• Associate with mitochondrial membranes
• Impair electron transport chain function
• Increase ROS production
• Trigger apoptotic pathways

• Accumulate in ER-associated compartments
• Activate PERK, IRE1, ATF6 pathways
• Lead to translational attenuation
• Trigger apoptosis if sustained

• Form pores in neuronal membranes
• Allow calcium influx
• Disrupt ionic homeostasis
• Activate calpain and caspase pathways

Conclusion

PSP represents the archetypal 4R tauopathy, with a distinct mechanistic profile from other tauopathies like CBD and AD. The selective accumulation of 4R tau isoforms, driven by MAPT H1 haplotype risk and exon 10 splicing dysregulation, produces a unique filament architecture (straight filaments with C-shaped protofilaments) that underlies the disease phenotype.

The clinical heterogeneity of PSP subtypes reflects differential regional vulnerability to tau pathology, from the classic Richardson syndrome (brainstem-predominant) to PSP-PAG (speech-predominant) and PSP-CBS (cortical-predominant). This variation offers opportunities for precision medicine approaches.

The therapeutic pipeline for PSP is maturing, with anti-tau antibodies (BIIB080, sartumab, gosuranemab), MAPT-targeting ASOs (BIIB080), and aggregation inhibitors in various stages of clinical development. Tau PET imaging enables patient selection and target engagement assessment, while fluid biomarkers (p-tau181, p-tau217, pS356) provide complementary diagnostic and monitoring tools.

Glial tau pathology — tufted astrocytes and coiled bodies — represents a distinguishing feature of PSP and an important therapeutic target. Understanding the interplay between neuronal and glial tau pathology will be critical for developing effective disease-modifying treatments.

See Also

• [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [Tau Aggregate Specificity in PSP](/mechanisms/psp-tau-aggregate-specificity)
• [Glial Tau Pathology in PSP and CBD](/mechanisms/glial-tau-pathology-psp-cbd)
• [Tau PET in CBS/PSP](/biomarkers/tau-pet-cbs-psp)
• [CBS vs PSP Comparison](/mechanisms/cbs-vs-psp-comparison)
• [MAPT Tau Aggregation PSP Causal Chain](/mechanisms/mapt-tau-aggregation-psp-causal-chain)
• [Progressive Supranuclear Palsy Disease Page](/diseases/progressive-supranuclear-palsy)

References